Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab monotherapy in Japanese RRMM
NCT02812706Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2016
- Primary completion
- Jul 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), sponsored by Sanofi. Started Sep 2016; status: completed.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02812706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02812706.